Countable Labs, Inc.

Countable Labs, Inc. is a US-based company specializing in innovative PCR technologies, focused on enhancing DNA and RNA quantification for diverse applications across research and clinical diagnostics. Countable Labs, Inc. was founded in 2019 and is headquartered in Palo Alto, US.

The company develops advanced PCR technologies, specifically its flagship product, Countable PCR. In May 2026, Countable Labs raised USD 26 mn in venture funding from investors including ARCH Venture Partners, F-Prime Capital, and Primer Ventures. This funding marked its latest round, bringing the total amount raised to USD 26 mn. The company has executed one deal to date.

Countable Labs specializes in innovative PCR technologies, with its core product being Countable PCR, a platform designed for precise quantification of DNA and RNA. This technology enhances sensitivity, reduces costs, and accelerates results compared to traditional digital PCR methods, while maintaining the simplicity of quantitative PCR. Countable PCR utilizes approximately 30 million compartments for true single-molecule counting, benefiting oncology, non-invasive prenatal testing, and infectious disease applications. The solutions are marketed primarily in North America, Europe, and Asia, catering to research institutions and clinical diagnostics.

Countable Labs generates revenue through the sale of its Countable PCR technology and related assay services, primarily on a B2B basis to research and clinical laboratories. Their transaction structure involves direct sales, including bulk orders and ongoing service agreements. Clients may form partnerships for customized assay solutions, with pricing structured around individual assays and service packages, allowing for efficient access to the platform and steady revenue from flagship offerings. Countable Labs plans to utilize the recent USD 26 mn funding raised in May 2026 to expand its product offerings and market reach.

The company is currently developing new products that aim to enhance its existing technology suite, with a focus on applications in oncology and infectious diseases. Additionally, Countable Labs seeks to penetrate new markets in Europe and Asia by 2027, enhancing its global footprint and meeting growing demand for high-precision molecular analysis.